Derivatives and methods of treating hepatitis B infections

A compound having the structure of Formula III:

• or a pharmaceutically acceptable salt thereof, wherein
• Y is —C(O)—;
• R1 is C3-C8-cycloalkyl or C2-C8-heterocyclyl, wherein cycloalkyl and heterocyclyl are optionally substituted with 1 or 2 groups each independently selected from —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O—C1-C6-alkyl, and C1-C6-alkyl-OH;
• R2 is, at each occurrence, independently selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O—C1-C6-alkyl, and C1-C6-alkyl-OH;
• R3 is selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O—C1-C6-alkyl, and C1-C6-alkyl-OH;
• R4 is selected from (CR8R9)p—C1-C9-heteroaryl and (CR8R9)p—C6-C12-aryl, wherein heteroaryl and aryl are optionally substituted with 1, 2, or 3 groups, each independently selected from —OH, halo, CN, C1-C6-alkyl, C1-C6-haloalkyl, —O—C1-C6-alkyl, and C1-C6-alkyl-OH;
• R7 is selected from H, C1-C6-alkyl, and C1-C6-alkyl-OH;
• R8 is, at each occurrence, independently selected from H, —OH, halo, C1-C6-alkyl, C1-C6-haloalkyl, —O—C1-C6-alkyl, and C1-C6-alkyl-OH;
• R9 is, at each occurrence, independently selected from H and C1-C6-alkyl;
• and
• p is 0, 1, 2, 3, or 4.